Novartis AG
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Xolair (omalizumab by Year
Xolair (omalizumab — allergic asthma, chronic spontaneous urticaria CSU & food allergies, ex-US + co-promotion) ($M)
Novartis Xolair (omalizumab: $1,723M in FY2025, up 4.9% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Xolair 2 | 1 723 | 1 643 | 5 | 4”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Xolair (omalizumab — allergic asthma, chronic spontaneous urticaria CSU & food allergies, ex-US + co-promotion) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,723 | +4.9% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,643 | +12.3% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,463 | +7.2% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,365 | -4.4% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 1,428 | +14.1% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 1,251 | +6.6% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 1,173 | +12.9% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 1,039 | +12.9% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 920 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up xolair (omalizumab
Cite this data
StockData. (2026). Novartis Xolair (omalizumab ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-xolair
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.